NCT06967961View on ClinicalTrials.gov

Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers

NARecruitingINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

July 23, 2025

Primary Completion Date

July 23, 2029

Study Completion Date

July 23, 2029

Conditions
Urothelial CarcinomaRenal CancerProstate AdenocarcinomaAdenocarcinoma of EndometriumCutaneous MelanomaSoft Tissue Sarcoma (STS)Nonseminomatous Germ Cell TumorSeminomatous Germ Cell TumorUpper Aerodigestive Tract CarcinomaCervical Carcinoma
Interventions
OTHER

For each enrolled patient, the sample described below will be collected as specific intervention intended for research purposes:

A blood sample will be taken before initiation of the metastatic treatment line and will be analyzed by 2 distinct methods. The total blood volume withdrawn per patient is approximately 30mL.

Trial Locations (1)

31059

RECRUITING

Oncopole Claudius Regaud, IUCT-O, Toulouse

All Listed Sponsors
lead

Institut Claudius Regaud

OTHER